Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566193 | 1.00 | LMNA (0.31) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL4842766 | 0.81 | LMNA (0.34) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL2562167 | 0.78 | LMNA (0.32) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL6840421 | 0.66 | LMNA (0.40) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL13821423 | 0.64 | RIPK1 (0.41) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL678573 | 0.63 | LMNA (0.42) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL20115678 | 0.63 | MLYCD (0.41) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL27377625 | 0.63 | LMNA (0.37) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL8524045 | 0.62 | ALDH1A1 (0.39) | LMNA | |
| SCHEMBL6057305 | 0.61 | MMP1 (0.44) | LMNAMMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856124-B1 | NEW SYNTHESIS OF A CAMPTOTHECIN SUBUNIT | HOFFMANN LA ROCHE (CH) | 2011-11-02 | — | — | EP | disclosed |
| US-7423152-B2 | Process for the manufacture of intermediates in camptothecin production | HOFFMAN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1856124-A1 | NEW SYNTHESIS OF A CAMPTOTHECIN SUBUNIT | F. Hoffmann-Roche AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089657-A1 | NEW SYNTHESIS OF A CAMPTOTHECIN SUBUNIT | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189807-A1 | Process for the manufacture of intermediates in camptothecin production | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189807-A1 | Process for the manufacture of intermediates in camptothecin production | TOP1, TOP2A, AMPD1 | LMNA 1931/4885MMP1 3300/4885MMP2 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.